Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study)

INTRODUCTION: In Japan, dipeptidyl peptidase-4 (DPP-4) inhibitors are frequently used as the treatment of choice for patients with type 2 diabetes. In some cases, however, poor glycaemic and body weight control issues persist despite treatment with DPP-4 inhibitors. Previous researchers have reveale...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:BMJ Open
Main Authors: Koshizaka, Masaya, Ishikawa, Ko, Ishikawa, Takahiro, Kobayashi, Kazuki, Takemoto, Minoru, Horikoshi, Takuro, Shimofusa, Ryota, Takahashi, Sho, Nagashima, Kengo, Sato, Yasunori, Tatsuno, Ichiro, Terano, Takashi, Hashimoto, Naotake, Kuribayashi, Nobuichi, Uchida, Daigaku, Yokote, Koutaro
פורמט: Artigo
שפה:Inglês
יצא לאור: BMJ Publishing Group 2017
נושאים:
Diabetes and Endocrinology
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5726071/
https://ncbi.nlm.nih.gov/pubmed/28490565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2016-015766
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים